基于炎症-营养-脂质代谢指标构建Peutz-Jeghers综合征辅助诊断模型的研究

注册号:

Registration number:

ChiCTR2600125067 

最近更新日期:

Date of Last Refreshed on:

2026-05-20 17:44:42 

注册时间:

Date of Registration:

2026-05-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于炎症-营养-脂质代谢指标构建Peutz-Jeghers综合征辅助诊断模型的研究

Public title:

Study on Constructing an Auxiliary Diagnostic Model for Peutz‑Jeghers Syndrome Based on Inflammation‑Nutrition‑Lipid Metabolism Indicators

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于炎症-营养-脂质代谢指标构建Peutz-Jeghers综合征辅助诊断模型的研究

Scientific title:

Study on Constructing an Auxiliary Diagnostic Model for Peutz‑Jeghers Syndrome Based on Inflammation‑Nutrition‑Lipid Metabolism Indicators

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曹振林 

研究负责人:

曹振林 

Applicant:

Cao Zhenlin 

Study leader:

Cao Zhenlin 

申请注册联系人电话:

Applicant telephone:

+86 13718687503

研究负责人电话:

Study leader's
telephone:

+86 10 63131111

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lele53626@163.com

研究负责人电子邮件:

Study leader's E-mail:

czl0320@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区永安路95号

研究负责人通讯地址:

北京市西城区永安路95号

Applicant address:

No.95 Yongan Road,Xicheng District,Beijing,China

Study leader's address:

No.95 Yongan Road,Xicheng District,Beijing,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京友谊医院

Applicant's institution:

Beijing Friendship Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京友谊医院

Affiliation of the Leader:

Beijing Friendship Hospital ,Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026-P2-213-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京友谊医院科研伦理委员会

Name of the ethic committee:

Research Ethics Committee of Beijing Friendship Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-04-17 00:00:00

伦理委员会联系人:

李悦

Contact Name of the ethic committee:

Li Yue

伦理委员会联系地址:

北京市西城区永安路95号

Contact Address of the ethic committee:

No.95 Yongan Road,Xicheng District,Beijing,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 63139006

伦理委员会联系人邮箱:

Contact email of the ethic committee:

13661202501@163.com

研究实施负责(组长)单位:

首都医科大学附属北京友谊医院

Primary sponsor:

Beijing Friendship Hospital ,Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区永安路95号

Primary sponsor's address:

No.95 Yongan Road,Xicheng District,Beijing,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院

具体地址:

北京市西城区永安路95号

Institution
hospital:

Beijing Friendship Hospital ,Capital Medical University

Address:

No.95 Yongan Road,Xicheng District,Beijing,China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-supporting

研究疾病:

Peutz-Jeghers综合征  

Target disease:

Peutz Jeghers syndrome

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

1、明确PJS患者的系统性病理特征; 2、筛选PJS发生的独立相关因素; 3、构建并评价多维度辅助诊断模型 4、探索低成本、非侵入性的筛查路径  

Objectives of Study:

1. Identify the systemic pathological features of PJS patients; 2. To screen the independent related factors of PJS; 3. Construct and evaluate a multi-dimensional auxiliary diagnosis model 4. Explore a low-cost, non-invasive screening pathway

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

PJS综合征患者:1.合并恶性肿瘤;2.近2周内有急性感染或大手术史;3.服用激素或降脂药者。 良性息肉患者:1.具有其他遗传性息肉病(如FAP);2.严重肝肾功能不全者;3.患者或家属拒绝参与该研究。 健康志愿者:1.患有高血压、糖尿病、高脂血症等代谢性疾病者。

Exclusion criteria:

PJS syndrome patients: 1. Complicated with malignant tumors; 2. History of acute infection or major surgery within the last 2 weeks; 3. Taking hormone or lipid-lowering drugs. Patients with benign polyps:1. other hereditary polyposis (e.g., FAP); 2. Severe hepatic and renal insufficiency; 3. Patients or their family members refused to participate in the study. Healthy volunteers: Patients with hypertension, diabetes, hyperlipidemia and other metabolic diseases.

研究实施时间:

Study execute time:

From 2026-04-06 00:00:00 To 2028-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-22 00:00:00 To 2028-06-01 00:00:00

干预措施:

Interventions:

组别:

黑斑息肉综合征患者组

样本量:

50

Group:

P-J syndrome patients group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

良性息肉患者组

样本量:

175

Group:

Benign polyp group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

健康志愿者组

样本量:

175

Group:

Healthy volunteers group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京友谊医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Friendship Hospital ,Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

炎症指标:PLT、PLR、NLR

指标类型:

主要指标

Outcome:

Inflammatory markers: platelet count (PLT), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

营养指标:TP、ALB、HB

指标类型:

主要指标

Outcome:

Nutritional indicators: total protein (TP), albumin (ALB), hemoglobin (HB)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢指标:TC、TG

指标类型:

主要指标

Outcome:

Metabolic indicators: total cholesterol (TC), triglycerides (TG)

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

AUC 值

指标类型:

主要指标

Outcome:

Area Under the Curve

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究为回顾性研究,数据采集基于医院信息管理系统(HIS)及电子病案系统。由研究人员根据预先设计的病例记录表(CRF),对符合纳入排除标准的研究对象进行数据提取,包括患者人口学信息、实验室检查结果(炎症、营养、脂质代谢指标)及基因检测结果等。提取数据由双人独立核对,确保准确性,统一录入数据库进行管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This is a retrospective study. Data were collected by extracting information from the Hospital Information System (HIS) and electronic medical record system. A standardized Case Record Form (CRF) was used to capture data including demographics, laboratory parameters (inflammatory, nutritional, and lipid metabolism markers), and genetic testing results for eligible patients. Data extraction was independently verified by two researchers for accuracy, and data were then entered into a database for management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-05-20 17:44:24